393 related articles for article (PubMed ID: 33189037)
21. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
[TBL] [Abstract][Full Text] [Related]
22. Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience.
Moretto R; Germani MM; Borelli B; Conca V; Rossini D; Boraschi P; Donati F; Urbani L; Lonardi S; Bergamo F; Cerma K; Ramondo G; D'Amico FE; Salvatore L; Valente G; Barbaro B; Giuliante F; Di Maio M; Masi G; Cremolini C
ESMO Open; 2024 Apr; 9(4):102991. PubMed ID: 38631269
[TBL] [Abstract][Full Text] [Related]
23. [Long-term outcomes of patients undergoing hepatectomy for bilateral multiple colorectal liver metastases-a propensity score matching analysis].
Bao Q; Wang K; Wang HW; Jin KM; Xing BC
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Oct; 23(10):976-983. PubMed ID: 33053993
[No Abstract] [Full Text] [Related]
24. Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases.
Galizia G; De Vita F; Lieto E; Zamboli A; Morgillo F; Castellano P; Mabilia A; Auricchio A; Renda A; Ciardiello F; Orditura M
Oncol Rep; 2013 Dec; 30(6):2992-8. PubMed ID: 24126855
[TBL] [Abstract][Full Text] [Related]
25. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer.
Jones RP; Hamann S; Malik HZ; Fenwick SW; Poston GJ; Folprecht G
Eur J Cancer; 2014 Jun; 50(9):1590-601. PubMed ID: 24661798
[TBL] [Abstract][Full Text] [Related]
26. [Conversion therapy for synchronous colorectal liver metastases].
Morohashi H; Yokoyama H; Akasaka H; Sakamoto Y; Koyama M; Murata A; Hakamada K
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1665-7. PubMed ID: 24393882
[TBL] [Abstract][Full Text] [Related]
27. Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution.
Ammori JB; Kemeny NE; Fong Y; Cercek A; Dematteo RP; Allen PJ; Kingham TP; Gonen M; Paty PB; Jarnagin WR; D'Angelica MI
Ann Surg Oncol; 2013 Sep; 20(9):2901-7. PubMed ID: 23771246
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy for patients with colorectal liver metastases who underwent curative resection improves long-term outcomes: systematic review and meta-analysis.
Araujo RL; Gönen M; Herman P
Ann Surg Oncol; 2015 Sep; 22(9):3070-8. PubMed ID: 25586244
[TBL] [Abstract][Full Text] [Related]
29. The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial.
Bolhuis K; Bond MJG; Van Amerongen MJ; Komurcu A; Chapelle T; Dejong CHC; Engelbrecht MRW; Gerhards MF; Grünhagen DJ; van Gulik TM; Hermans JJ; De Jong KP; Kazemier G; Klaase JM; Kok NFM; Leclercq WKG; Liem MSL; van Lienden KP; Molenaar IQ; Neumann UP; Patijn GA; Rijken AM; Ruers TM; Verhoef C; de Wilt JHW; May AM; Punt CJA; Swijnenburg RJ;
Eur J Cancer; 2023 Apr; 183():49-59. PubMed ID: 36801606
[TBL] [Abstract][Full Text] [Related]
30. [Perioperative chemotherapy in patients with colorectal cancer liver metastasis].
Xu D; Xing BC
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):321-328. PubMed ID: 31054545
[TBL] [Abstract][Full Text] [Related]
31. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
33. [Specific treatment situations in metastatic colorectal cancer].
Arnold D; Schmoll HJ; Lang H; Knoefel WT; Ridwelski K; Trarbach T; Staib L; Kirchner T; Geissler M; Seufferlein T; Amthauer H; Riess H; Schlitt HJ; Piso P
Onkologie; 2010; 33 Suppl 4():8-18. PubMed ID: 20431307
[TBL] [Abstract][Full Text] [Related]
34. Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
Boilève A; De Cuyper A; Larive A; Mahjoubi L; Najdawi M; Tazdait M; Gelli M; Tselikas L; Smolenschi C; Malka D; Pignon JP; Ducreux M; Boige V
Eur J Cancer; 2020 Oct; 138():89-98. PubMed ID: 32871526
[TBL] [Abstract][Full Text] [Related]
35. Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Kullmann F; Scheithauer W; Scholz M; Müller S; Link H; Rost A; Höffkes HG; Moehler M; Lindig RU; Miller-Phillips L; Kirchner T; Jung A; von Einem JC; Modest DP; Heinemann V
Int J Cancer; 2018 Mar; 142(5):1047-1055. PubMed ID: 29047142
[TBL] [Abstract][Full Text] [Related]
36. Regional chemotherapy of non-resectable liver metastases from colorectal cancer - literature and institutional review.
Link KH; Kornmann M; Formentini A; Leder G; Sunelaitis E; Schatz M; Pressmar J; Beger HG
Langenbecks Arch Surg; 1999 Aug; 384(4):344-53. PubMed ID: 10473854
[TBL] [Abstract][Full Text] [Related]
37. Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases.
Chan DL; Alzahrani NA; Morris DL; Chua TC
Surg Oncol; 2015 Sep; 24(3):162-71. PubMed ID: 26133575
[TBL] [Abstract][Full Text] [Related]
38. Survival and Prognostic Factors of Colorectal Liver Metastases After Surgical and Nonsurgical Treatment.
Lemke J; Cammerer G; Ganser J; Scheele J; Xu P; Sander S; Henne-Bruns D; Kornmann M
Clin Colorectal Cancer; 2016 Dec; 15(4):e183-e192. PubMed ID: 27269232
[TBL] [Abstract][Full Text] [Related]
39. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA;
BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708
[TBL] [Abstract][Full Text] [Related]
40. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
Lévi FA; Boige V; Hebbar M; Smith D; Lepère C; Focan C; Karaboué A; Guimbaud R; Carvalho C; Tumolo S; Innominato P; Ajavon Y; Truant S; Castaing D; De Baere T; Kunstlinger F; Bouchahda M; Afshar M; Rougier P; Adam R; Ducreux M;
Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
